Spring Bank Pharmaceuticals (SBPH) Upgraded to “Hold” by ValuEngine

ValuEngine upgraded shares of Spring Bank Pharmaceuticals (NASDAQ:SBPH) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning.

Separately, Cantor Fitzgerald restated an overweight rating and set a $32.00 target price (up from $29.00) on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, February 21st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $28.00.

How to Become a New Pot Stock Millionaire

SBPH stock opened at $13.50 on Wednesday. Spring Bank Pharmaceuticals has a fifty-two week low of $7.95 and a fifty-two week high of $18.93.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its earnings results on Tuesday, February 20th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.18. analysts expect that Spring Bank Pharmaceuticals will post -2.4 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in SBPH. Wells Fargo & Company MN purchased a new position in Spring Bank Pharmaceuticals in the fourth quarter valued at approximately $101,000. Virtu Financial LLC purchased a new position in Spring Bank Pharmaceuticals in the fourth quarter valued at approximately $172,000. Candriam Luxembourg S.C.A. purchased a new position in Spring Bank Pharmaceuticals in the fourth quarter valued at approximately $269,000. BlackRock Inc. increased its stake in Spring Bank Pharmaceuticals by 14.8% in the fourth quarter. BlackRock Inc. now owns 32,961 shares of the company’s stock valued at $443,000 after purchasing an additional 4,259 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Spring Bank Pharmaceuticals in the fourth quarter valued at approximately $676,000. Institutional investors own 28.65% of the company’s stock.

WARNING: “Spring Bank Pharmaceuticals (SBPH) Upgraded to “Hold” by ValuEngine” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3337806/spring-bank-pharmaceuticals-sbph-upgraded-to-hold-by-valuengine.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Invitae  Receiving Somewhat Positive Media Coverage, Analysis Shows
Invitae Receiving Somewhat Positive Media Coverage, Analysis Shows
Sterling Construction  Receives Daily Coverage Optimism Rating of 0.12
Sterling Construction Receives Daily Coverage Optimism Rating of 0.12
Cedar Realty Trust  Getting Somewhat Positive Press Coverage, Accern Reports
Cedar Realty Trust Getting Somewhat Positive Press Coverage, Accern Reports
Reviewing Gorman-Rupp  & ITT
Reviewing Gorman-Rupp & ITT
Comparing Aqua Metals  and Constellium
Comparing Aqua Metals and Constellium
Reviewing Navigant Consulting  and Its Rivals
Reviewing Navigant Consulting and Its Rivals


© 2006-2018 Ticker Report. Google+.